Table 1.
Formulation1 | In vitro release at 4 h | Maximum inhibition of airway hyperreactivity | Maximum inhibition of pulmonary edema |
---|---|---|---|
100% rolipram | 70% | 100% | Not significant |
40% rolipram/60% PLGA | 36% | 100% | 48% |
40% rolipram/55% PLGA/5% PEG | 56% | 100% | Not significant |
All generated by spray drying of methylene chlorine solutions using 0.4 mm nozzle; PLGA formulations contain 50:50 ratio of lactide:glycolide.